Fundraising FoxPsyMed Ventures — 2021 Investments
5 investments dated 2021 · listed companies and verified rows first · show all
AtaiBeckley develops rapid-acting and durable mental health treatments for patients with difficult-to-treat mental health conditions.
BiotechMedical DevicesMental Health
Christian AngermayerCosmo Feilding Mellen(Founder)inSrinivas Rao
Co-investorsBailey Venture PartnersFJ LabsIter InvestmentsLeafy TunnelMaiora Rebel VenturesNoetic+4 more
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
David Olson(Founder)David Olson Nick Haft(Founder)Nick Haft(Founder)
Co-investorsArtis VenturesBailey Venture PartnersCasa Verde CapitalDolby Family VenturesGaingelsNoetic+8 more
__Twitter.png)
Journey Clinical provides ketamine-assisted psychotherapy (KAP) for depression, anxiety, and PTSD, partnering patients with licensed therapists and medical teams while coordinating with major insurance providers.
Digital HealthMedical DevicesMental Health
Jonathan Sabbagh(Founder)inMyriam Barthes(Founder)in
Co-investorsAble PartnersAlleyCorpCoalition OperatorsFifty YearsFJ LabsGaingels+9 more
Reset Pharma is a CNS-focused pharmaceutical company developing psilocybin and related psychedelics for the treatment of mental illness in patients with life-threatening diseases.
BiotechDigital HealthHealthtechMental HealthNew York, US
John Andreadis(Executive Officer, Director)Jan-Anders Karlsson(Executive Officer, Director)Philip Taub(Director)Tim Schlidt(Director)
Co-investorsGaingelsIter Investments
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Mindstate
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.